Ipamorelin
Ipamorelin is a synthetic peptide that acts as a selective agonist at the ghrelin receptor (GHS-R1a), stimulating growth hormone release from the pituitary. It was developed in the 1990s and is characterized in the literature by a comparatively clean profile — minimal effect on cortisol or prolactin relative to earlier GHRPs.
Mechanism
- Ghrelin receptor (GHS-R1a) agonism. Stimulates pulsatile GH release from the anterior pituitary.
- Selectivity. Notably does not significantly increase cortisol or prolactin in the doses commonly studied — differentiating feature from GHRP-6 and GHRP-2.
Common research protocols
Dosing information below reflects published research literature. It is not medical advice and is not a treatment plan.
- Common research doses. Approximately 100-300 mcg per injection, subcutaneous, once or multiple times daily in research protocols.
- Frequently paired with. A GHRH analog (Sermorelin, CJC-1295) to synergistically stimulate GH release.
Evidence at a glance
- Human data. Studied in short-term human trials for GH-releasing effect. Not FDA-approved for human use.
- Known effects. Transient increase in serum GH; downstream IGF-1 elevation with continued use.
Reconstitution & handling
Lyophilized peptides ship as freeze-dried powder. Reconstitute with bacteriostatic water; refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How It Works page.
Primary-literature list for this guide available on request via contact.